Stock Track | AKESO Plummets 5.42% Intraday as FY2025 Loss Widens to CNY 1.1 Billion Despite Revenue Growth

Stock Track03-27

AKESO's stock price dropped 5.42% during the intraday session following the release of its full-year 2025 financial results, which showed a widening annual loss despite strong revenue growth.

The biopharmaceutical company reported that its revenue increased by 43.9% to CNY 3.1 billion for FY2025, driven by commercial momentum from its immuno-oncology products cadonilimab and ivonescimab after their first inclusion in China's national reimbursement drug list. However, the company's loss attributable widened significantly to CNY 1.11 billion, which appears to have disappointed investors and triggered the sell-off.

While Akeso highlighted progress in its pipeline strategy centered on bispecific antibodies and expansion into additional therapeutic areas, and noted that overseas development for ivonescimab advanced through partner Summit Therapeutics with a BLA submission accepted by the FDA, the substantial widening of losses overshadowed these positive developments in today's trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1157373460?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 09:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157373460","market":"us","top_or_hot":-1,"title":"Stock Track | AKESO Plummets 5.42% Intraday as FY2025 Loss Widens to CNY 1.1 Billion Despite Revenue Growth","media":"Stock Track","content":"<p>AKESO's stock price dropped 5.42% during the intraday session following the release of its full-year 2025 financial results, which showed a widening annual loss despite strong revenue growth.</p><p>The biopharmaceutical company reported that its revenue increased by 43.9% to CNY 3.1 billion for FY2025, driven by commercial momentum from its immuno-oncology products cadonilimab and ivonescimab after their first inclusion in China's national reimbursement drug list. However, the company's loss attributable widened significantly to CNY 1.11 billion, which appears to have disappointed investors and triggered the sell-off.</p><p>While Akeso highlighted progress in its pipeline strategy centered on bispecific antibodies and expansion into additional therapeutic areas, and noted that overseas development for ivonescimab advanced through partner Summit Therapeutics with a BLA submission accepted by the FDA, the substantial widening of losses overshadowed these positive developments in today's trading.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | AKESO Plummets 5.42% Intraday as FY2025 Loss Widens to CNY 1.1 Billion Despite Revenue Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | AKESO Plummets 5.42% Intraday as FY2025 Loss Widens to CNY 1.1 Billion Despite Revenue Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-27 09:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AKESO's stock price dropped 5.42% during the intraday session following the release of its full-year 2025 financial results, which showed a widening annual loss despite strong revenue growth.</p><p>The biopharmaceutical company reported that its revenue increased by 43.9% to CNY 3.1 billion for FY2025, driven by commercial momentum from its immuno-oncology products cadonilimab and ivonescimab after their first inclusion in China's national reimbursement drug list. However, the company's loss attributable widened significantly to CNY 1.11 billion, which appears to have disappointed investors and triggered the sell-off.</p><p>While Akeso highlighted progress in its pipeline strategy centered on bispecific antibodies and expansion into additional therapeutic areas, and noted that overseas development for ivonescimab advanced through partner Summit Therapeutics with a BLA submission accepted by the FDA, the substantial widening of losses overshadowed these positive developments in today's trading.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1157373460","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157373460","pubTimestamp":1774575082,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"AKESO's stock price dropped 5.42% during the intraday session following the release of its full-year 2025 financial results, which showed a widening annual loss despite strong revenue growth.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"个股追踪|康方生物盘中暴跌5.42%营收增长2025财年亏损扩大至11亿元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"AKESO's stock price dropped 5.42% during the intraday session following the release of its full-year 2025 financial results, which showed a widening annual loss despite strong revenue growth.The biopharmaceutical company reported that its revenue increased by 43.9% to CNY 3.1 billion for FY2025, driven by commercial momentum from its immuno-oncology products cadonilimab and ivonescimab after their first inclusion in China's national reimbursement drug list. However, the company's loss attributable widened significantly to CNY 1.11 billion, which appears to have disappointed investors and triggered the sell-off.While Akeso highlighted progress in its pipeline strategy centered on bispecific antibodies and expansion into additional therapeutic areas, and noted that overseas development for ivonescimab advanced through partner Summit Therapeutics with a BLA submission accepted by the FDA, the substantial widening of losses overshadowed these positive developments in today's trading.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1157373460","isCrawlerRequest":true}